Bruce Soloway
Abstract
On September 30, 2004, Merck voluntarily withdrew its cyclooxygenase (COX)-2 inhibitor rofecoxib (Vioxx) from the market. The action followed analysis
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
On September 30, 2004, Merck voluntarily withdrew its cyclooxygenase (COX)-2 inhibitor rofecoxib (Vioxx) from the market. The action followed analysis
Key concepts: Medicine, Rofecoxib, Biochemistry, Chemistry, Cyclooxygenase, Enzyme